This discovery paves the way for a possible therapeutic application in AMBRA1-deficient melanomas of FAK1 inhibitors, which are already exploited in preclinical models of melanoma with acquired resistance to BRAFi49, and in clinical trials for solid tumors42,50,51. This evidence concerns the gene AMBRA1 and melanoma.